Newly developed CancerLinQ Discovery translates Big Data into practical knowledge for cancer community
CancerLinQ, a nonprofit subsidiary of the American Society of Clinical Oncology (ASCO), today announced CancerLinQ Discovery, a groundbreaking offering that will provide insights through the analysis of real-world cancer care data. CancerLinQ Discovery will provide highly curated, de-identified sets of clinical data with the objective of creating new clinical knowledge and improving patient outcomes. It will derive these sets from the rapidly-growing CancerLinQ® database, which now includes over 1.5 million patient records and more than 70 oncology practices that have agreed to contribute data to CancerLinQ's core quality improvement and data-sharing platform.
CancerLinQ also announced a new non-exclusive partnership with AstraZeneca, which will use CancerLinQ Discovery to gather insights on specific cancer care questions and provide critical input to maximize CancerLinQ Discovery's utility and usability. In addition, CancerLinQ is pursuing collaborations with government agencies, medical specialty societies and additional life sciences companies. Through all these efforts, CancerLinQ hopes to gain insights that can improve quality and efficiency of the cancer care delivery system.
"As CancerLinQ itself scales up to help doctors assess and improve their care in everyday practice, CancerLinQ Discovery will leverage our collaboration to enable the entire care and research community to explore some of our most pressing treatment and scientific challenges," said Clifford A. Hudis, MD, Chief Executive Officer of ASCO and Chair of the CancerLinQ board. "Contributing to our shared goal of improving clinical care, we recognize AstraZeneca for its commitment to accelerate that progress and unlock new insights through the CancerLinQ Discovery learning platform."